Dr Reddy's Laboratories has become the first Indian pharmaceutical company to launch an anti-cancer drug in the Chinese market, India's ambassador to China Vikram Misri tweeted.

"Some good news this week - a breakthrough for the Indian pharmaceutical industry in China as Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market," Misri tweeted.

Abiraterone Acetate, which was launched in the US in 2020, is used in treating prostate cancer.

The drug is a therapeutic generic version of Zytiga owned by Johnson & Johnson.

In China, Dr Reddy’s operate as a joint venture and it's called KunshanRotam Reddy Pharmaceutical Co.